Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke

Wunderlich, Michael T.; Hanhoff, Thorsten; Görtler, Michael; Spener, Friedrich; Glatz, Jan F. C.; Wallesch, C. W.; Pelsers, Maurice M.A.L.

doi:10.1055/s-2004-833221

Cited by 26 publications

(41 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although many biomarkers are shown to have potential in the diagnosis of acute ischemic stroke, none of them are clinically practical at present [9,18,23]. Among these biomarkers, S100 protein, NSE, H-FABP, ApoC-I and ApoC-III are frequently studied [1,5,9,10,13,22,23]. A recent study showed that the sensitivity and specificity of H-FABP, NSE and S100 protein for stroke diagnosis were 68.2 %, 55 %, 15 % and 100 %, 36.4 %, 95.5 % [9].…”

Section: Discussionmentioning

confidence: 98%

“…These markers have been assessed for their values in stroke diagnosis, severity, treatment and prognosis [13][14][15][16][17][18][19][20][21]. Among these markers, myelin basic protein, S100 protein, neuron-specific enolase (NSE), glial fibrillary acidic protein, heart-fatty acid binding protein (H-FABP), apolipoprotein CI (ApoC-I) and apolipoprotein CIII (ApoC-III) are frequently studied [5,9,10,13,22].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Serum free hemoglobin as a novel potential biomarker for acute ischemic stroke

Huang

Chen

et al. 2009

J Neurol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

mentioning

confidence: 99%

Serum free hemoglobin as a novel potential biomarker for acute ischemic stroke

Huang

Chen

et al. 2009

J Neurol

View full text Add to dashboard Cite

show abstract

“…Therefore, H-FABP has been used diagnostic marker for acute coronary syndromes. On the other hand, previous studies have demonstrated that serum level of H-FABP is increased in patients with hypertrophic and dilated cardiomyopathy, heart failure, stroke, obstructive sleep apnea syndrome, pulmonary embolism [5][6][7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 96%

Serum heart type fatty acid binding protein levels in metabolic syndrome

Akbal

Özbek

Güneş

et al. 2009

Endocr

View full text Add to dashboard Cite

Heart type fatty acid binding protein (H-FABP) is a major cytoplasmic low-molecular weight protein and released into the circulation when the myocardium is injured. Previous studies have demonstrated that H-FABP is closely associated with acute coronary syndrome, hypertrophic and dilated cardiomyopathy, heart failure, stroke, obstructive sleep apnea syndrome, pulmonary embolism. The aim of this study was to investigate serum H-FABP value in the patients with metabolic syndrome (MetS). We measured serum H-FABP levels in 55 consecutive patients with MetS, and 73 age-matched control subjects by using a sandwich enzyme-linked immunosorbent assay. Serum H-FABP levels were significantly higher in patients with MetS than in control subjects 18.37 ± 13.0 and 7.9 ± 6.5 ng/ml, respectively, (P < 0.001). Serum H-FABP levels were significantly higher in patients with diabetic MetS than in without diabetic MetS, 24.0 ± 10.2 and 13.9 ± 12.6 ng/ml, respectively, (P: 0,003). There were statistically significant differences between patients without diabetic MetS and control subjects, 13.8 ± 12.6 and 7.9 ± 6.5 ng/ml, respectively, (P = 0.023). Patients with MetS have an increased risk of death from cardiovascular diseases. H-FABP seems to be a marker that will enable the detection of cardiac injury in the early asymptomatic period in patients with MetS.

show abstract

“…They are thought to develop from the persistent population of embryonal neural crest cells that would otherwise either differentiate or undergo apoptosis [1,2,12]. Neuroblastic tumors are remarkable for their diverse pathological features, with a wide range of neuroblastic differentiation and amount Brain lipid-binding protein is a member of the large family of FABPs, which are small nonenzymatic cytoplasmic lipid-binding proteins with a molecular weight of 14 to 15 kd, involved in the buffering and transport of long-chain fatty acids, gene expression, and cellular growth and differentiation [13]. Brain lipid-binding protein is expressed at high levels in the developing central nervous system [5,14,15], and its gene is located at chromosome 6q22-23 [6].…”

Section: Discussionmentioning

confidence: 99%